Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rabinder Bhatti

Pain Medicine Daytona Beach, FL Doctor of Osteopathy

NPI 1275709818 CMS profile 628008

1671 N Clyde Morris Blvd Ste 100, Daytona Beach, FL 32117

Open in the dashboard

General payments

$6,288

230 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rabinder Bhatti of Daytona Beach, FL is reported in the CMS Open Payments database as having received $6,288 across 230 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $652 13
2024 General $211 19
2023 General $1,085 68
2022 General $904 35
2021 General $923 36
2020 General $729 28
2019 General $1,784 31

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rabinder Bhatti
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Rabinder Bhatti were reported at $652. Among 1,144 Pain Medicine profiles paid that year, the median was $402 and the middle half received between $130 and $1,173.

Show as a table
Year Rabinder Bhatti Pain Medicine median Middle half National median
2019 $1,784 $409 $115–$1,311 $163
2020 $729 $214 $66–$666 $114
2021 $923 $299 $84–$899 $132
2022 $904 $335 $103–$1,149 $149
2023 $1,085 $376 $114–$1,228 $160
2024 $211 $387 $115–$1,173 $164
2025 $652 $402 $130–$1,173 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic USA, Inc. $2,177 39 payments
  2. Boston Scientific Corporation $1,893 105 payments
  3. Medtronic, Inc. $522 18 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $258 14 payments
  5. Abbott Laboratories $220 4 payments
  6. Scilex Pharmaceuticals Inc. $205 12 payments
  7. Vertos Medical, Inc. $142 2 payments
  8. Collegium Pharmaceutical, Inc. $126 7 payments
  9. Relievant Medsystems, Inc. $107 1 payment
  10. SPR Therapeutics, Inc $94 1 payment
  11. Other $544 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,282 226 payments
  2. Travel and Lodging $985 3 payments
  3. Education $21 1 payment
Products named General payments · program years 2019–2025
  1. WaveWriter Alpha Prime 16 $1,173 77 payments
  2. INTELLIS $1,160 9 payments
  3. MYSTIM $721 20 payments
  4. SYNCHROMED Drug Infusion Systems $296 10 payments
  5. RELISTOR $240 13 payments
  6. SYNCHROMED Drug Infusion Systems $232 5 payments
  7. ETERNA $172 1 payment
  8. General - Pain Management $143 4 payments
  9. mild Device Kit $142 2 payments
  10. Intracept $140 1 payment
  11. Other $1,813 81 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

126

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$2,028

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

43.7%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 41 $917
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 14 $406
Gabapentin Generic 17 $264
Tizanidine Hcl Generic 20 $228
Naproxen Generic 15 $126
Tramadol Hcl Generic 19 $87

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$8,684

Medicare's payments for the services billed

Medicare patients

66

Average age 74

Services billed

121

42 women, 24 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
COPD 36%
Depression 33%
Diabetes 32%
Ischemic heart disease 30%
Chronic kidney disease 29%
Osteoporosis 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

230 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record